{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:46:34Z","timestamp":1790142394380,"version":"4.0.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Medical Innovation Project of Fujian Provincial Health Commission","award":["2022CXA017"],"award-info":[{"award-number":["2022CXA017"]}]},{"name":"Fujian Provincial Natural Science Foundation of China","award":["2025J01781"],"award-info":[{"award-number":["2025J01781"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Microbiol"],"DOI":"10.1186\/s12866-025-04331-7","type":"journal-article","created":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T06:46:53Z","timestamp":1756190813000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["In vitro activity of Eravacycline against carbapenem-resistant gram-negative bacilli and associated risk factors for non-susceptible infections from a tertiary hospital in fujian, China from 2021 to 2024"],"prefix":"10.1186","volume":"25","author":[{"given":"Xuyang","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengfei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiyun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,26]]},"reference":[{"issue":"10459","key":"4331_CR1","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/S0140-6736(24)01867-1","volume":"404","author":"GBD 2021 Antimicrobial Resistance Collaborators","year":"2024","unstructured":"GBD 2021 Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance 1990\u20132021: a systematic analysis with forecasts to 2050. Lancet. 2024;404(10459):1199\u2013226.","journal-title":"Lancet"},{"issue":"0","key":"4331_CR2","first-page":"S521","volume":"69","author":"N Patrice","year":"2019","unstructured":"Patrice N, Laurent P. Epidemiology and diagnostics of carbapenem resistance in Gram-negative bacteria [J]. Clin Infect Dis. 2019;69(0):S521\u20138.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"4331_CR3","first-page":"421","volume":"11","author":"A Caterina","year":"2022","unstructured":"Caterina A, Pasquale S, Manlio B, et al. Mechanisms of action of carbapenem resistance [J]. Antibiot (Basel). 2022;11(3):421.","journal-title":"Antibiot (Basel)"},{"issue":"0","key":"4331_CR4","first-page":"1394775","volume":"15","author":"Q Zhilang","year":"2024","unstructured":"Zhilang Q, Kexin Y, Huijun C, et al. Cross-talk of MLST and transcriptome unveiling antibiotic resistance mechanism of carbapenem resistance Acinetobacter baumannii clinical strains isolated in guiyang, China [J]. Front Microbiol. 2024;15(0):1394775.","journal-title":"Front Microbiol"},{"issue":"11","key":"4331_CR5","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1517\/13543784.2014.965253","volume":"23","author":"M Bassetti","year":"2014","unstructured":"Bassetti M, Righi E. Eravacycline for the treatment of intra-abdominal infections. Expert Opin Investig Drugs. 2014;23(11):1575\u201384.","journal-title":"Expert Opin Investig Drugs"},{"issue":"6","key":"4331_CR6","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1080\/14787210.2024.2351552","volume":"22","author":"P Huang","year":"2024","unstructured":"Huang P, Hsu C, Tang H, et al. Eravacycline: a comprehensive review of in vitro activity, clinical efficacy, and real-world applications. Expert Rev Anti-infect Ther. 2024;22(6):387\u201398.","journal-title":"Expert Rev Anti-infect Ther"},{"issue":"3","key":"4331_CR7","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1002\/phar.2366","volume":"40","author":"S Alosaimy","year":"2020","unstructured":"Alosaimy S, Abdul-Mutakabbir J, Kebriaei R, et al. Evaluation of eravacycline: A novel fluorocycline [J]. Pharmacotherapy. 2020;40(3):221\u201338.","journal-title":"Pharmacotherapy"},{"issue":"1","key":"4331_CR8","first-page":"139","volume":"7","author":"Z Jin-Xin","year":"2018","unstructured":"Jin-Xin Z, Zhi-Wei L, Xiang S, et al. Overexpression of OqxAB and macab efflux pumps contributes to Eravacycline resistance and heteroresistance in clinical isolates of Klebsiella pneumoniae [J]. Emerg Microbes Infect. 2018;7(1):139.","journal-title":"Emerg Microbes Infect"},{"issue":"12","key":"4331_CR9","doi-asserted-by":"publisher","first-page":"7357","DOI":"10.1128\/AAC.01503-16","volume":"60","author":"J Chih-Han","year":"2016","unstructured":"Chih-Han J, Yi-Wei H, Yi-Tsung L, et al. Risk factors, outcomes, and mechanisms of Tigecycline-Nonsusceptible Klebsiella pneumoniae bacteremia [J]. Antimicrob Agents Chemother. 2016;60(12):7357\u201363.","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"4331_CR10","doi-asserted-by":"publisher","first-page":"5743","DOI":"10.1128\/AAC.00827-13","volume":"57","author":"N Masayuki","year":"2013","unstructured":"Masayuki N, Catalina Salinas C, Krystina W, et al. Nested case-control study of the emergence of Tigecycline resistance in multidrug-resistant Klebsiella pneumoniae [J]. Antimicrob Agents Chemother. 2013;57(11):5743\u20136.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"4331_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12866-024-03525-9","volume":"24","author":"S Lian","year":"2024","unstructured":"Lian S, Liu C, Cai M, et al. Risk factors and molecular characterization of carbapenem resistant Escherichia coli recovered from a tertiary hospital in Fujian, China from 2021 to 2023. BMC Microbiol. 2024;24(1): 374.","journal-title":"BMC Microbiol"},{"key":"4331_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2024.107769","volume":"153","author":"L Zha","year":"2025","unstructured":"Zha L, Li S, Guo J, et al. Global and regional burden of bloodstream infections caused by carbapenem-resistant Gram-negative bacteria in 2019: a systematic analysis from the MICROBE database. Int J Infect Dis. 2025;153: 107769.","journal-title":"Int J Infect Dis"},{"issue":"6","key":"4331_CR13","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1080\/14787210.2024.2351552","volume":"22","author":"H Po-Yu","year":"2024","unstructured":"Po-Yu H, Chi-Kuei H, Hung-Jen T, et al. Eravacycline: a comprehensive review of in vitro activity, clinical efficacy, and real-world applications [J]. Expert Rev Anti Infect Ther. 2024;22(6):387\u201398.","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"1","key":"4331_CR14","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1186\/s12879-019-4093-1","volume":"19","author":"Z Chunjiang","year":"2019","unstructured":"Chunjiang Z, Xiaojuan W, Yawei Z, et al. In vitro activities of Eravacycline against 336 isolates collected from 2012 to 2016 from 11 teaching hospitals in China [J]. BMC Infect Dis. 2019;19(1):508.","journal-title":"BMC Infect Dis"},{"issue":"0","key":"4331_CR15","first-page":"1471469","volume":"14","author":"W Zhiren","year":"2024","unstructured":"Zhiren W, Henan L. The Tigecycline resistance mechanisms in Gram-negative bacilli [J]. Front Cell Infect Microbiol. 2024;14(0):1471469.","journal-title":"Front Cell Infect Microbiol"},{"issue":"0","key":"4331_CR16","first-page":"S17","volume":"72","author":"EN Richard","year":"2021","unstructured":"Richard EN, Kelly MH, Hannah W, et al. National estimates of healthcare costs associated with Multidrug-Resistant bacterial infections among hospitalized patients in the united States [J]. Clin Infect Dis. 2021;72(0):S17\u201326.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"4331_CR17","first-page":"e01699","volume":"64","author":"M Ian","year":"2019","unstructured":"Ian M, Melanie O, Stephen H, et al. In vitro activity of Eravacycline against Gram-Negative bacilli isolated in clinical laboratories worldwide from 2013 to 2017 [J]. Antimicrob Agents Chemother. 2019;64(3):e01699\u201319.","journal-title":"Antimicrob Agents Chemother"},{"issue":"0","key":"4331_CR18","first-page":"S206","volume":"221","author":"Q Xiaohua","year":"2020","unstructured":"Xiaohua Q, Shi W, Min H, et al. The colonization of Carbapenem-Resistant Klebsiella pneumoniae: epidemiology, resistance mechanisms, and risk factors in patients admitted to intensive care units in China [J]. J Infect Dis. 2020;221(0):S206\u201314.","journal-title":"J Infect Dis"},{"key":"4331_CR19","doi-asserted-by":"crossref","unstructured":"F B, M C N MIM et al. Antibiotic-selective environments [J]. Clin Infect Dis 27(s1):5\u201311.","DOI":"10.1086\/514916"},{"key":"4331_CR20","doi-asserted-by":"crossref","unstructured":"Zheng J, Lin Z, Sun X, et al. Overexpression of OqxAB and macab efflux pumps contributes to Eravacycline resistance and heteroresistance in clinical isolates of Klebsiella pneumoniae [J]. Volume 7. Emerging microbes & infections; 2018. p. 139. 1.","DOI":"10.1038\/s41426-018-0141-y"},{"issue":"1","key":"4331_CR21","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1093\/jac\/dku340","volume":"70","author":"S Bialek-Davenet","year":"2015","unstructured":"Bialek-Davenet S, Lavigne J, Guyot K, et al. Differential contribution of AcrAB and OqxAB efflux pumps to multidrug resistance and virulence in Klebsiella pneumoniae. J Antimicrob Chemother. 2015;70(1):81\u20138.","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"4331_CR22","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1089\/mdr.2015.0258","volume":"23","author":"R Li","year":"2017","unstructured":"Li R, Han Y, Zhou Y, et al. Tigecycline susceptibility and molecular resistance mechanisms among clinical Klebsiella pneumoniae strains isolated during non-tigecycline treatment. Microbial Drug Resistance 2017;23(2):139\u201346.","journal-title":"Microbial Drug Resistance"},{"issue":"10","key":"4331_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0165019","volume":"11","author":"L Fang","year":"2016","unstructured":"Fang L, Chen Q, Shi K, et al. Step-wise increase in Tigecycline resistance in Klebsiella pneumoniae associated with mutations in ramr, Lon and RpsJ. PLoS One. 2016;11(10): e0165019.","journal-title":"PLoS One"},{"issue":"10","key":"4331_CR24","doi-asserted-by":"publisher","first-page":"400","DOI":"10.3390\/microorganisms7100400","volume":"7","author":"C Correa-Martinez","year":"2019","unstructured":"Correa-Martinez C, Stollenwerk V, Kossow A, et al. Risk factors for long-term vancomycin-resistant Enterococci persistence-a prospective longitudinal study. Microorganisms. 2019;7(10):400","journal-title":"Microorganisms"}],"container-title":["BMC Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12866-025-04331-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12866-025-04331-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12866-025-04331-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T00:45:07Z","timestamp":1757465107000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmicrobiol.biomedcentral.com\/articles\/10.1186\/s12866-025-04331-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,26]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4331"],"URL":"https:\/\/doi.org\/10.1186\/s12866-025-04331-7","relation":{},"ISSN":["1471-2180"],"issn-type":[{"value":"1471-2180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,26]]},"assertion":[{"value":"22 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Medical Ethics Committee of Fujian Medical University Union Hospital (2024KY300) approved the exempt review and written or oral informed consent was waived.We affirm that the execution of this study adhered to the principles outlined in the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"551"}}